Nasal immunization with compound 48/80-adjuvanted acellular pertussis vaccines is an effective strategy to induce pertussis-specific systemic and mucosal immunity.
Alison Hofmann Church, Soman N Abraham, Herman F Staats, Brandi T Johnson-Weaver
{"title":"Nasal immunization with compound 48/80-adjuvanted acellular pertussis vaccines is an effective strategy to induce pertussis-specific systemic and mucosal immunity.","authors":"Alison Hofmann Church, Soman N Abraham, Herman F Staats, Brandi T Johnson-Weaver","doi":"10.7774/cevr.2025.14.e23","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Mast cell activating adjuvants induce vaccine-specific systemic and mucosal immunity when administered intranasally. <i>Bordetella pertussis</i> infects the respiratory tract and caused 0.45% childhood mortality in the United States before implementing pertussis vaccines. Pertussis infections are resurging. Immunity induced by current pertussis vaccines wanes quickly, possibly due to vaccine-induced T helper (Th) 2 and weak mucosal immunity. <i>B. pertussis</i> induces Th1, Th17, and mucosal immunoglobulin A (IgA) immunity, providing durable protection against disease. Next-generation pertussis vaccines that induce Th1, Th17, and IgA immunity may reduce the resurgence of pertussis. This study determined if nasal pertussis vaccines adjuvanted with the mast cell activator compound 48/80 (C48/80) modulate pertussis-specific immunity.</p><p><strong>Materials and methods: </strong>Mice received intranasal C48/80-adjuvanted pertussis vaccines or subcutaneous aluminum-adjuvanted pertussis vaccines. Immunized mice were challenged with <i>B. pertussis</i> and monitored for protection against infection. Pertussis-specific immune profiles were characterized after immunization. A C48/80 and CpG adjuvant combination was evaluated to enhance pertussis-specific Th1 immunity.</p><p><strong>Results: </strong>Alum-adjuvanted pertussis vaccines induce Th2 immunity and undetectable IgA responses. Nasal C48/80-adjuvanted pertussis vaccines enhance pertussis-specific serum and mucosal IgA and Th2 and Th17 responses but not Th1 immunity. The C48/80 and CpG adjuvant combination enhances systemic and mucosal pertussis-specific Th1, Th17, and IgA compared to unadjuvanted pertussis vaccines, which may be the desired immune response to protect against pertussis infections.</p><p><strong>Conclusion: </strong>We demonstrate that nasal pertussis vaccines containing C48/80 adjuvants induce pertussis-specific IgA, Th1-, and Th17-associated immunity when combined with CpG, which may be an effective strategy to improve pertussis vaccines.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"14 3","pages":"246-260"},"PeriodicalIF":1.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303703/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7774/cevr.2025.14.e23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/15 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Mast cell activating adjuvants induce vaccine-specific systemic and mucosal immunity when administered intranasally. Bordetella pertussis infects the respiratory tract and caused 0.45% childhood mortality in the United States before implementing pertussis vaccines. Pertussis infections are resurging. Immunity induced by current pertussis vaccines wanes quickly, possibly due to vaccine-induced T helper (Th) 2 and weak mucosal immunity. B. pertussis induces Th1, Th17, and mucosal immunoglobulin A (IgA) immunity, providing durable protection against disease. Next-generation pertussis vaccines that induce Th1, Th17, and IgA immunity may reduce the resurgence of pertussis. This study determined if nasal pertussis vaccines adjuvanted with the mast cell activator compound 48/80 (C48/80) modulate pertussis-specific immunity.
Materials and methods: Mice received intranasal C48/80-adjuvanted pertussis vaccines or subcutaneous aluminum-adjuvanted pertussis vaccines. Immunized mice were challenged with B. pertussis and monitored for protection against infection. Pertussis-specific immune profiles were characterized after immunization. A C48/80 and CpG adjuvant combination was evaluated to enhance pertussis-specific Th1 immunity.
Results: Alum-adjuvanted pertussis vaccines induce Th2 immunity and undetectable IgA responses. Nasal C48/80-adjuvanted pertussis vaccines enhance pertussis-specific serum and mucosal IgA and Th2 and Th17 responses but not Th1 immunity. The C48/80 and CpG adjuvant combination enhances systemic and mucosal pertussis-specific Th1, Th17, and IgA compared to unadjuvanted pertussis vaccines, which may be the desired immune response to protect against pertussis infections.
Conclusion: We demonstrate that nasal pertussis vaccines containing C48/80 adjuvants induce pertussis-specific IgA, Th1-, and Th17-associated immunity when combined with CpG, which may be an effective strategy to improve pertussis vaccines.
期刊介绍：
Clin Exp Vaccine Res, the official English journal of the Korean Vaccine Society, is an international, peer reviewed, and open-access journal. It covers all areas related to vaccines and vaccination. Clin Exp Vaccine Res publishes editorials, review articles, special articles, original articles, case reports, brief communications, and correspondences covering a wide range of clinical and experimental subjects including vaccines and vaccination for human and animals against infectious diseases caused by viruses, bacteria, parasites and tumor. The scope of the journal is to disseminate information that may contribute to elaborate vaccine development and vaccination strategies targeting infectious diseases and tumors in human and animals. Relevant topics range from experimental approaches to (pre)clinical trials for the vaccine research based on, but not limited to, basic laboratory, translational, and (pre)clinical investigations, epidemiology of infectious diseases and progression of all aspects in the health related issues. It is published printed and open accessed online issues (https://ecevr.org) two times per year in 31 January and 31 July. Clin Exp Vaccine Res is linked to many international databases and is made freely available to institutions and individuals worldwide
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
